IRL790
NOVEL THERAPEUTIC FOR THE TREATMENT OF PARKINSONS DISEASE
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IRL790 project word cloud
Explore the words cloud of the IRL790 project. It provides you a very rough idea of what is the project "IRL790" about.
Project "IRL790" data sheet
The following table provides information about the project.
| Coordinator |
INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Project website | http://www.irlab.se/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-11-01 to 2019-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB | SE (GOTEBORG) | coordinator | 50˙000.00 |
Map
Project objective
This project’s goal is to develop a successful treatment that combats severe motor and psychotic symptoms in Parkinson’s disease (PD). PD is a debilitating neurodegenerative disorder affecting > 6 million people worldwide. It’s the neurological disorder with the highest increase in death rates, prevalence, and disability-adjusted life-years (DALYs). Levodopa, introduced more than 50 years ago, remains the most prescribed treatment for the symptomatic relief of PD, although its long-term use leads to the development of motor complications, i.e. levodopa-induced dyskinesia (PD-LIDs). IRLAB aims to address the challenge in PD treatment by clinically validating its novel compound, IRL790, aimed at reducing symptoms of PD-LIDs and Parkinson’s disease psychosis. IRLAB’s programme is based on its proprietary drug discovery platform, Integrative Screening Process (ISP), which captures a better understanding of complexities of CNS-related diseases, such as PD, and yields drug candidates with superior chance of success in the clinic. IRLAB’s therapeutic will improve intervention outcomes for PD patients in two indications. Its safety and tolerability have been validated in Phase I clinical trials and its therapeutic efficacy in PD-LIDs is being evaluated in an ongoing Phase II study. Results are expected 2018. Besides medical benefits to patients, IRL790 has also the potential to bring cost-savings to healthcare providers by effectively reducing the Parkinson’s disease burden. Generation of high quality clinical data will improve IRLAB’s opportunities for out-licensing. We plan to apply for SME grant to accelerate clinical developmental and take IRL790 through a Phase II study in PD psychosis. This way, we will out-license and market the drug sooner and for two indications (PD-LIDs and PD psychosis) simultaneously. IRLAB has an established business development contact network and have gained trust of international healthcare investors and national innovation funding bodies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRL790" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IRL790" are provided by the European Opendata Portal: CORDIS opendata.